Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Prostrate Cancer Drug Moves into Human Clinical Trials

Published: Monday, May 19, 2014
Last Updated: Monday, May 19, 2014
Bookmark and Share
ADC Therapeutics announced that it has selected its first IND candidate under its joint development agreement with MedImmune.

This follows the October 2013 announcement in which MedImmune entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCT’s antibody-drug conjugate programs in preclinical development.

ADCT-401 targets Prostate-Specific Membrane Antigen (PSMA) a cell-surface antigen specifically expressed by prostate cancer cells. ADCT-401 comprises an anti-PSMA monoclonal antibody coupled with a pyrrolobenzodiazepine (PBD) warhead using a proprietary linker licensed from London-based Spirogen, a wholly owned subsidiary of MedImmune.  Initial clinical studies will focus on hormone-refractory prostate cancer and an IND filing is anticipated in 2015.

“We are excited by the preclinical efficacy data we have seen with ADCT-401 in a number of in vivo models of prostate cancer.  These data have encouraged us to continue development of this unique ADC for the treatment of refractory prostate cancer.  ADCT-401 was constructed and tested by the joint ADCT and Spirogen teams, and we are very pleased with the outcome,” said Dr. Peter B. Corr, Chairman of ADCT and Co-Founder and Managing General Partner of Auven Therapeutics, the private equity firm behind the formation of ADCT and its majority shareholder.

The PSMA-specific J591 antibody in ADCT-401 was developed by Dr. Neil H. Bander, the Bernard & Josephine Chaus Professor of Urologic Oncology and Director of Urological Oncology Research at the Weill-Cornell Medical College, New York.  Dr. Bander is also Chairman of ADCT’s Scientific Advisory Board. PSMA is a cell-surface antigen expressed by virtually all prostate cancer cells, including metastases, and also in the blood vessels that feed many other tumor types, but is rarely expressed in normal cells.

“PSMA is an ideal target for an ADC therapeutic strategy because it is unparalleled in its prostate cancer specificity, its high density of expression and its very efficient internalization,” said Dr. Neil Bander. “If the preclinical efficacy and safety studies translate into the clinic, ADCT-401 has the potential to be a breakthrough therapy in the treatment of advanced, refractory prostate cancers. I am delighted that the ADCT and MedImmune teams have combined their efforts to advance it into patients as quickly as possible,” he added.

This will be ADCT’s second ADC program into the clinic from its pipeline of eleven programs with an IND filing expected in the first of these programs by the end of this year.  

“We are optimistic that continued investigations of ADCT-401 in patients with prostate cancer will deliver the results we expect. The program is a testament to the close teamwork, commitment to scientific excellence and sense of urgency shared between the MedImmune and ADC Therapeutics teams on this project,” said Stephen Evans-Freke, Co-founder and Managing General Partner of Auven Therapeutics.

The pre-clinical development of ADCT-401 is being managed by a team of scientists based in laboratories at the Queen Mary Bioenterprises Innovation Centre, London which, being co-located with Spirogen, enables close co-operation between the two groups.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ADC Therapeutics Appoints CEO
Company announces appointment of Dr. Chris Martin.
Tuesday, June 23, 2015
ADCT Appoints Senior VP of R&D
Appointment of former Genmab vice president Dr Patrick van Berkel as senior vice president.
Thursday, July 19, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!